Physician profile
Elizabeth A Egan
NPI 1174685416
$10,609.00
in general payments reported to CMS, 2019-2025
34 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $793 · 2021: $1,157 · 2022: $1,552 · 2023: $1,725 · 2024: $2,272 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,210.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,110.95 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,673.37 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $961.72 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $691.01 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $667.32 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $518.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $478.14 | 2022-2025 | Dupixent |
| Celgene Corporation | $451.55 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $212.29 | 2021-2023 | |
| Medtronic USA, INC. | $203.26 | 2019-2020 | |
| Lilly USA, LLC | $181.53 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $171.55 | 2020-2024 | |
| Celltrion USA INC. | $170.46 | 2024-2025 | Vegzelma |
| Conmed Corporation | $168.83 | 2025 | Conmed Hemostasis, Conmed Biliary, Conmed Dilation |
| Ardelyx, INC. | $166.12 | 2023-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $120.60 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $112.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $93.02 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $70.65 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $68.68 | 2019-2023 | Dificid |
| Gilead Sciences, INC. | $40.52 | 2019-2021 | |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Ipsen Biopharmaceuticals, INC | $38.70 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $31.19 | 2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $28.62 | 2019 | |
| Novo Nordisk INC | $21.03 | 2025 | Wegovy |
| Theratechnologies INC. | $17.25 | 2023 | Egrifta, Trogarzo |
| Ge Healthcare | $16.82 | 2025 | |
| Romark Laboratories, Lc | $16.60 | 2019 | |
| Evoke Pharma, INC. | $14.86 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Sutab |
| Intercept Pharmaceuticals, INC. | $12.51 | 2020 | |
| Redhill Biopharma INC. | $12.41 | 2021 | |
| Allergan, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.